Literature DB >> 11992057

Use of extended systematic sampling in patients with a prior negative prostate needle biopsy.

Chris H Chon1, Frank C Lai, John E McNeal, Joseph C Presti.   

Abstract

PURPOSE: We examine the potential impact of extended systematic biopsy schemes in patients with a prior negative prostate biopsy.
MATERIALS AND METHODS: Between January 1999 and March 2001, 185 patients with a prior negative prostate needle biopsy underwent repeat biopsy. Systematic 10 core biopsies (sextant, lateral mid gland and lateral base) were performed in all patients. A subset of 111 patients underwent 6 additional biopsies directed anteriorly. All biopsy results were reviewed by a single pathologist. The overall and unique cancer detection rates were calculated for each biopsy site. McNemar's test was then used to compare the yield of various simulated biopsy schemes to define the optimal biopsy regimen.
RESULTS: Overall, 67 of 185 patients (36%) were found to have cancer on repeat biopsy. The highest detection rate was found for the apex, lateral base and lateral mid sites. The mid lobar base site consistently yielded the lowest detection rate. These results were mirrored in the unique cancer detection rate calculations. The traditional sextant scheme detected only 73% of tumors. Using a lateral sextant scheme (apex, lateral mid gland and lateral base), the detection rate increased to 85% (p = 0.15). An 8 core biopsy scheme (apex, mid gland, lateral mid gland and lateral base) increased the detection rate to 95%. However, there was no significant increase in cancer detection rate when the 8 core scheme was compared to the 10 core scheme. The 6 anteriorly directed biopsies uniquely detected only 2 cancers.
CONCLUSIONS: We recommend that patients with a prior negative prostate biopsy who are undergoing repeat biopsy receive at least an 8 core biopsy scheme weighted toward the lateral aspect of the prostate.

Entities:  

Mesh:

Year:  2002        PMID: 11992057

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  Simulation optimization of PSA-threshold based prostate cancer screening policies.

Authors:  Daniel J Underwood; Jingyu Zhang; Brian T Denton; Nilay D Shah; Brant A Inman
Journal:  Health Care Manag Sci       Date:  2012-12

2.  Prostate biopsy: targeting cancer for detection and therapy.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2006

3.  Optimizing prostate biopsy strategies for the diagnosis of prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2003

Review 4.  Anatomic and Molecular Imaging in Prostate Cancer.

Authors:  Eric T Miller; Amirali Salmasi; Robert E Reiter
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

5.  The Efficacy of Target Biopsy of Suspected Cancer Lesions Detected by Magnetic Resonance Imaging and/or Transrectal Ultrasonography during Initial Prostate Biopsies: Comparison of Outcomes between Two Physicians.

Authors:  Hideto Iwamoto; Tetsuya Yumioka; Noriya Yamaguchi; Seiya Inoue; Toshihiko Masago; Shuichi Morizane; Akihisa Yao; Masashi Honda; Takehiro Sejima; Atsushi Takenaka
Journal:  Yonago Acta Med       Date:  2014-04-28       Impact factor: 1.641

6.  The effect of prior biopsy scheme on prostate cancer detection for repeat biopsy population: results of the 14-core prostate biopsy technique.

Authors:  Saadettin Yilmaz Eskicorapci; Fuad Guliyev; Ekrem Islamoglu; Ali Ergen; Haluk Ozen
Journal:  Int Urol Nephrol       Date:  2006-06-01       Impact factor: 2.370

Review 7.  Urologic imaging for localized prostate cancer in 2007.

Authors:  Tillmann Loch
Journal:  World J Urol       Date:  2007-03-21       Impact factor: 4.226

Review 8.  Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning.

Authors:  Steven Sidelsky; Shaan Setia; Srinivas Vourganti
Journal:  Curr Urol Rep       Date:  2017-10-18       Impact factor: 3.092

9.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

10.  Distribution of prostate carcinoma foci within the peripheral zone: analysis of 8,062 prostate biopsy cores.

Authors:  C Brossner; A Winterholer; M Roehlich; E Dlouhy-Schütz; V Serra; M Sonnleithner; K H Grubmüller; K Pummer; E Schuster
Journal:  World J Urol       Date:  2003-06-03       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.